Edition:
United Kingdom

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

1.93USD
7:32pm BST
Change (% chg)

$-0.03 (-1.53%)
Prev Close
$1.96
Open
$1.98
Day's High
$1.98
Day's Low
$1.93
Volume
10,655
Avg. Vol
23,122
52-wk High
$3.29
52-wk Low
$1.02

Chart for

About

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $34.19
Shares Outstanding(Mil.): 16.21
Dividend: --
Yield (%): --

Financials

  AEZS.OQ Industry Sector
P/E (TTM): -- 85.48 32.76
EPS (TTM): -1.81 -- --
ROI: -80.47 2.29 14.61
ROE: -309.50 3.86 16.34

BRIEF-Aeterna Zentaris Reports Qtrly Earnings Per Share $0.87

* AETERNA ZENTARIS REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

07 May 2018

BRIEF-Aeterna Zentaris Qtrly Loss Per Share $0.03

* AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS

28 Mar 2018

BRIEF-Aeterna Zentaris Appoints James Clavijo As CFO

* AETERNA ZENTARIS APPOINTS JAMES CLAVIJO AS CHIEF FINANCIAL OFFICER

05 Mar 2018

BRIEF-Aeterna Zentaris Provides Update On Previously Disclosed Class Action Lawsuit

* AETERNA ZENTARIS PROVIDES UPDATE ON PREVIOUSLY DISCLOSED CLASS ACTION LAWSUIT

05 Mar 2018

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

17 Jan 2018

Earnings vs. Estimates